4.10Open4.10Pre Close0 Volume51 Open Interest145.00Strike Price0.00Turnover218.58%IV39.86%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry4.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0808Delta0.0016Gamma57.14Leverage Ratio-0.5648Theta-0.0073Rho-4.62Eff Leverage0.0644Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet